198Au-labeled hydroxymethyl phosphines as models for potential therapeutic pharmaceuticals

Nuclear Medicine and Biology

Volumn 25, Issue 6, 1998, Pages 577-583

  Berning, D E ^a   Katti, K V ^a   Volkert, W A ^a,b   Higginbotham, C J ^b   Ketring, A R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b HS Truman Memorial VA Hospital   (United States)

Author keywords

Gold 198; Radiopharmaceuticals; Water soluble phosphines

Indexed keywords

1,2 BIS[BIS(HYDROXYMETHYL)PHOSPHINO]BENZENE AU 198; 1,2 BIS[BIS(HYDROXYMETHYL)PHOSPHINO]ETHANE AU 198; GOLD 198; GOLD COMPLEX; LIGAND; PHOSPHINE DERIVATIVE AU 198; RADIOPHARMACEUTICAL AGENT; TRIS(HYDROXYMETHYL)PHOSPHINE AU 198; UNCLASSIFIED DRUG; GOLD; PHOSPHINE DERIVATIVE;

ARTICLE; DRUG STABILITY; DRUG SYNTHESIS; PH; THERMOSTABILITY; ANIMAL; CHEMISTRY; HUMAN; ISOTOPE LABELING; RAT; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; DRUG STABILITY; GOLD RADIOISOTOPES; HUMANS; HYDROGEN-ION CONCENTRATION; ISOTOPE LABELING; PHOSPHINES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0031595063     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00023-7     Document Type: Article

References (19)

1. Berglof F.E., Berglof K., Walz D.T. Auranofin An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis . J. Rheumatol. 5:1987;68-74.
2. Berners-Price S.J., Mirabelli C.K., Johnson R.K., Mattern M.R., McCabe F.L., Faucette L.F., et al. In vivo antitumor activity and in vivo cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res. 46:1986;5486-5493.
3. + gold(I) complexes . Chem. Ber. 130:(7):1997;907-911.
4. 2Cl . Inorg. Chem. 36:1997;2765-2769.
5. Berning D.E., Reddy V.S., Katti K.V., Singh P.R., Hoffman T.J., Volkert W.A., et al. New technetium-99m and rhenium complexes of novel water-soluble bis phosphines. J. Labeled Radiopharm. 37:1995;459-461.
6. 99mTc complex with tris(hydroxymethyl)phosphine (THP). Nucl. Med. Biol. 23:1996;617-622.
7. 2OH). J. Chem. Soc., Dalton Trans. 1973;2021-2028.
8. Dash K.C., Schmidbaur H. Sigel H. Metal Ions in Biological Systems. 1982;179-205 Marcel Dekker, New York.
9. 3OH . Inorg. Chem. 31:1992;3026-3033.
10. Ficker S.P. Medicinal chemistry and pharmacology of gold compounds. Transition Met. Chem. 21:1996;377-383.
11. Hoye P.A.T., Pringle P.G., Smith M.B., Worboys K. Hydrophosphination of formaldehyde catalyzed by tris(hydroxymethyl)phosphine complexes of platinum, palladium or nickel. J. Chem. Soc., Dalton Trans. 1993;269-274.
12. Lewis J.S., Dearling J., Rooney B., Coley H., Kelland L., Zweit J., et al. Cationic copper-bis(diphosphine) complexes Potential agents for in vivo evaluation of multi-drug resistance by PET . Q. J. Nucl. Med. 41:(suppl.):1997;8.
13. Mirabelli C.K., Johnson R.K., Hill D.T., Faucette L.F., Girard G.R., Kuo G.Y., et al. Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J. Med. Chem. 29:1986;218-223.
14. Mirabelli C.K., Johnson R.K., Sung C.M., Faucette L., Muirhead K., Crooke S.T. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 45:1985;32-39.
15. 2}Cl . Inorg. Chem. 35:1996;1753-1757.
16. 2}2Cl. J. Chem. Soc., Dalton Trans. 1996;1301-1304.
17. Schubiger P.A., Alberto R., Smith A. Vehicles, chelators, and radionuclides Choosing the "building blocks" of an effective therapeutic radioimmunoconjugate . Bioconjug. Chem. 7:1996;165-179.
18. Simon T.M., Kunishima D.H., Vibert G.J., Lorber A. Screening trial with the coordinated gold compound auranofin using mouse lymphocytic leukemia P388. Cancer Res. 41:1981;94-97.
19. Volkert W.A., Goeckeler W.F., Ehrhardt G.J., Ketring A.R. Therapeutic radionuclides Production and decay property considerations . J. Nucl. Med. 32:1991;174-185.